'One Health' for the people of Hong Kong and the world by Jin, D et al.
Title 'One Health' for the people of Hong Kong and the world
Author(s) Kok, KH; Tang, VHM; Jin, D
Citation Science China Life Sciences, 2012
Issued Date 2012
URL http://hdl.handle.net/10722/188877
Rights Creative Commons: Attribution 3.0 Hong Kong License
SCIENCE CHINA 
Life Sciences 
© The Author(s) 2012. This article is published with open access at Springerlink.com life.scichina.com   www.springer.com/scp 
                  
*Corresponding author (email: dyjin@hku.hk) 
SPECIAL TOPIC: Translational medicine in China II doi: 10.1007/s11427-012-4408-6  
 doi: 10.1007/s11427-012-4408-6  
‘One Health’ for the people of Hong Kong and the world 
KOK Kin-Hang, TANG Hei-Man Vincent & JIN Dong-Yan* 
Department of Biochemistry, University of Hong Kong, Hong Kong, China 
Received October 3, 2012; accepted November 26, 2012 
 
Citation:  Kok K H, Tang H M V, Jin D Y. ‘One Health’ for the people of Hong Kong and the world. Sci China Life Sci, 
doi: 10.1007/s11427-012-4408-6  
 
 
 
Translational medicine refers to the conversion of scientific 
discoveries into improvements in medical practice. ‘From 
bench to bedside and back’ is a phrase that is often used to 
describe the two-way information flow in translational 
medicine. On one hand, scientists working at the bench 
make new discoveries that enable clinicians to revolutionize 
patient care, while on the other hand, clinical investigations 
at the bedside provide new knowledge about diseases, 
which stimulate basic research at the bench.  
One recent success story that illustrates the ‘from bench 
to bedside and back’ nature of translational medicine con-
cerns the development of small-molecule inhibitors of the 
Bcr-Abl fusion oncoprotein as therapeutics for chronic my-
eloid leukemia (CML). The discovery of the Philadelphia 
chromosome by Janet Rowley in 1973 and the study of the 
Bcr-Abl fusion oncoprotein expressed exclusively in CML 
cells finally led to the rational design and development of 
imatinib for clinical use. Imatinib is an ATP analog that 
impedes the binding of ATP to Bcr-Abl tyrosine kinase and 
thereby inhibits its oncogenic activity. Initial therapy of 
CML with imatinib results in complete remission and min-
imal side effects in approximately 70% of patients. The 
success of imatinib is rare in the history of cancer medicine 
and represents the start of a new era of molecularly-targeted 
cancer therapy. However, the potency of imatinib to inhibit 
Bcr-Abl is relatively low and resistance develops in patients 
through various new mutations in Bcr-Abl. These clinical 
investigations at the bedside stimulated new directions for 
basic research at the bench. The consequent biochemical, 
molecular and pharmacological studies to address these 
questions have given rise to the second-generation Bcr-Abl 
inhibitors dasatinib and nilotinib, which are superior to 
imatinib. These inhibitors are 20- to 300-fold more potent 
than imatinib in inhibiting Bcr-Abl. In particular, the con-
formation-dependent binding of dasatinib to Bcr-Abl ren-
ders the development of resistance through single point 
mutations more difficult. Dasatinib and nilotinib are there-
fore recommended for clinical use at the bedside as 
front-line therapy for CML [1,2].  
Translational medicine aspires to bridge the gap between 
basic and clinical medicine, which involves the daunting 
task of breaking down existing barriers between biomedical 
scientists and clinicians. These barriers are particularly 
strong in mainland China, where biomedical science and 
clinical medicine have developed into separate professions. 
Communication among scientists and clinicians from dif-
ferent disciplines and institutions has to be re-established 
and substantially enhanced with the aim of cross-fertilizing 
new ideas, strategies and innovations in disease prevention 
and intervention. In keeping with this main theme of trans-
lational medicine, we would like to go one step further by 
introducing and promoting the concept of ‘One Health’ [3]. 
The goals of the ‘One World-One Medicine-One Health’ 
initiative are to “promote, improve, and defend the health 
and well-being of all species by enhancing cooperation and 
collaboration between physicians, veterinarians, other sci-
entific health and environmental professionals” (http://www. 
onehealthinitiative.com/). The idea is to expand the dia-
logues and collaborations in “all aspects of health care for 
humans, animals and the environment”. These collabora-
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tions must be coequal and all inclusive. They should engage 
physicians, osteopaths, veterinarians, dentists, nurses as 
well as other scientific, health and environmentally-related 
disciplines. In reality, uniting human and veterinary medi-
cine represents another daunting challenge in mainland 
China for historical and other reasons. In one extreme case, 
human virologists were prohibited by law from touching 
dead birds infected by the H5N1 influenza virus found in 
the area near Qinghai Lake.  
One fundamental issue in translational medicine and in 
the ‘One Health’ initiative is the integration of basic and 
clinical medicines. Hong Kong, as the gateway from China 
to the world and vice versa, is not only a city where East 
meets West, but also a place where modern medicine was 
introduced to save the lives of many people. Looking back 
in history, several major medical discoveries that were ini-
tially made in Hong Kong in the past decades have had sig-
nificant and long-lasting impacts on the world. Notably, 
pioneering clinician scientists in Hong Kong have already 
set excellent examples for the integration of basic and clin-
ical medicines. In this perspective, they were also exempla-
ry practitioners of translational medicine or ‘One Medicine’. 
What we need to do in the pursuit of translational medicine 
or ‘One Health’ in today’s changing world, is to learn from 
these pioneers in Hong Kong’s history. Here we review the 
anecdotal records of Sir Patrick Manson’s pioneering work 
on Filaria in the 1880s and the discovery of severe acute 
respiratory syndrome (SARS) coronavirus in 2003. 
Sir Patrick Manson (1844–1922) was the founding Dean 
of the Hong Kong College of Medicine for Chinese in 1886, 
which became the Faculty of Medicine of the University of 
Hong Kong in 1911. Dr. Sun Yat-sen was one of Manson’s 
first medical students and Manson also used his influence in 
1896 to ensure the release of Sun from custody by Qing 
officials in London. Manson practiced medicine privately in 
Hong Kong in 1883–1889. Before he came to Hong Kong, 
he also saw patients in Taiwan for 5 years and in Xiamen 
for 13 years. Manson was a great physician and surgeon 
who was already famous in Taiwan for performing surgery 
on a 19-year-old man suffering from elephantiasis caused 
by Filaria. He saw patients on a daily basis and saved the 
lives of many people infected with parasites using his med-
ical and surgical techniques. Fascinated by these medically 
important research questions that he encountered during his 
private practice in Hong Kong, Manson later went back to 
London to found the London School of Tropical Medicine, 
where he carried out parasitological research that led to the 
identification of Schistosoma mansoni, the cause of a com-
mon form of schistosomiasis. He was also instrumental in 
providing the first evidence for the involvement of an ar-
thropod vector in the life cycle of a parasite. Under his su-
pervision, Ronald Ross fully documented the role of mos-
quitoes as a vector of malaria and was awarded the Nobel 
Prize in 1902 for this discovery. All these research findings 
are truly ground-breaking and have had a tremendous im-
pact on patient care and the practice of medicine, as well as 
disease prevention and control. Manson was therefore 
known as the ‘Father of Tropical Medicine’ [4,5]. 
In the past 120 years, the tradition of pursuing excellence 
in patient care and medical research, which can be traced 
back to the early life and work of Sir Patrick Manson, has 
been carried on by generations of scientists and clinicians in 
Hong Kong. This was well illustrated when Hong Kong was 
hit by SARS in 2003. It is now unequivocally accepted that 
the SARS coronavirus, which is responsible for SARS, was 
discovered by a group of scientists and clinicians at the 
University of Hong Kong led by Prof. Malik Peiris and Prof. 
K. Y. Yuen [6]. In our opinion, this was accomplished at 
this university rather than elsewhere for several reasons. 
First, the leading virologists and clinicians in this group had 
the expertise and management skills for tackling medically 
important problems using a multidisciplinary approach. 
Second, the University of Hong Kong has a strong infra-
structure that facilitates the discovery of new etiologic 
agents, including a well-integrated research unit in which 
clinical samples are collected and various kinds of microbi-
ological assays are systemically performed. This organiza-
tion is perfectly suited to the purpose of clinical and transla-
tional microbiological research. Third, the group had 
learned from previous success in the study of influenza vi-
ruses. It is particularly noteworthy that the H5N1 influenza 
virus was also identified by the same group [7]. Finally, the 
group was small but functional, and familiar not only with 
the most advanced molecular and high-throughput technol-
ogies, but also able to employ all the classical methods for 
virus isolation and characterization. Of note, the success in 
identifying the SARS coronavirus was attributed to neither 
‘big science’ nor ‘big grants’. They succeeded in the face of 
fierce competition from American and European groups 
only because they were good and because they used the 
right approach. Ten years after the identification of the 
SARS coronavirus, many other groups that jumped into the 
field after the outbreak of SARS have left, while the teams 
at the University of Hong Kong continued to make major 
contributions to the field. The recently identified group 2c 
human coronavirus EMC associated with one severe and 
two fatal cases of respiratory syndrome in Saudi Arabia was 
most closely related to two bat coronaviruses identified by 
Hong Kong scientists in 2007 [8,9]. Thus, the findings ob-
tained by scientists at the University of Hong Kong have 
shaped the field of coronavirus research for years to come. 
Their ground-breaking and continuing work in the field has 
been translated into new strategies, reagents and assays for 
the prevention and control of infectious diseases. In this 
sense, they have provided another successful example of the 
‘from bench to bedside and back’ model in translational 
medicine and ‘One Health’.  
The integration of basic and clinical medicine is highly 
characteristic of the life and work of Sir Patrick Manson 
who founded the Medical Faculty of the University of Hong 
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Kong and the London School of Tropical Medicine. It was 
also the key to the success in the identification of the SARS 
coronavirus in Hong Kong about 110 years later. This 
should also be the guiding principle of translational medi-
cine and ‘One Health’ as well. The ultimate goal of both is 
to promote human health and well being. To this end, free 
access to information, samples and resources is of funda-
mental importance. If Manson had not tested his great ideas 
that originated from his medical practices in Hong Kong, 
Taiwan and Xiamen with carefully designed experiments in 
mosquitoes, he would never have made the discoveries that 
later transformed modern medicine. If Prof. Yuen and col-
leagues in the University of Hong Kong had not had access 
to the wild animals with the help of veterinarians and other 
professionals, they would never have traced the SARS-like 
coronaviruses to bats [10]. Learning from the successful 
experience of pioneering scientists who worked in Hong 
Kong will help identify major deficiencies in the infrastruc-
ture for medical research in mainland China. Cracking the 
institutional and disciplinary barriers that hamper commu-
nication and collaboration between scientists and clinicians 
is an essential prerequisite for the future development of 
translational medicine and ‘One Health’.     
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